Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Findlay

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Drug Intelligence & Clinical Pharmacy|November 1, 1982
An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteersJ H Hull, J W Findlay, J F Rogers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1992
Disposition of acrivastine in the male beagle dogM J McNulty, D L Deal, F R Nelson, et al.
Investigational New Drugs|January 1, 1994
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinomaJ Berlin, A C King, K Tutsch, et al.
Anesthesiology|May 1, 1983
Biphasic depression of ventilatory responses to CO2 following epidural morphineE R Kafer, J T Brown, D Scott, et al.
British Journal of Clinical Pharmacology|July 1, 1986
Comparative disposition of codeine and pholcodine in man after single oral dosesJ W Findlay, A S Fowle, R F Butz, et al.
Clinical Pharmacy|November 1, 1984
Bioavailability of pseudoephedrine and triprolidine from combination and single-ingredient productsB O Williams, S H Liao, A A Lai, et al.
Clinical Pharmacology and Therapeutics|August 1, 1982
Codeine disposition in smokers and nonsmokersJ F Rogers, J W Findlay, J H Hull, et al.
European Journal of Clinical Pharmacology|January 1, 1981
Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjectsJ W Findlay, J Van Wyck Fleet, P G Smith, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 9, 2000
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspectiveJ W Findlay, W C Smith, J W Lee, et al.
Clinical Pharmacology and Therapeutics|October 1, 1993
Disposition of digoxin immune Fab in patients with kidney failureM R Ujhelyi, S Robert, D M Cummings, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Drug Intelligence & Clinical Pharmacy|November 1, 1982
An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteersJ H Hull, J W Findlay, J F Rogers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1992
Disposition of acrivastine in the male beagle dogM J McNulty, D L Deal, F R Nelson, et al.
Investigational New Drugs|January 1, 1994
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinomaJ Berlin, A C King, K Tutsch, et al.
Anesthesiology|May 1, 1983
Biphasic depression of ventilatory responses to CO2 following epidural morphineE R Kafer, J T Brown, D Scott, et al.
British Journal of Clinical Pharmacology|July 1, 1986
Comparative disposition of codeine and pholcodine in man after single oral dosesJ W Findlay, A S Fowle, R F Butz, et al.
Clinical Pharmacy|November 1, 1984
Bioavailability of pseudoephedrine and triprolidine from combination and single-ingredient productsB O Williams, S H Liao, A A Lai, et al.
Clinical Pharmacology and Therapeutics|August 1, 1982
Codeine disposition in smokers and nonsmokersJ F Rogers, J W Findlay, J H Hull, et al.
European Journal of Clinical Pharmacology|January 1, 1981
Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjectsJ W Findlay, J Van Wyck Fleet, P G Smith, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 9, 2000
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspectiveJ W Findlay, W C Smith, J W Lee, et al.
Clinical Pharmacology and Therapeutics|October 1, 1993
Disposition of digoxin immune Fab in patients with kidney failureM R Ujhelyi, S Robert, D M Cummings, et al.
Pageof 6